Priority 11 from the Psoriasis PSP
|UNCERTAINTY: Are oral and biological treatments for psoriasis safe to use for people with psoriasis or their partner if they are trying to have a baby, and are they safe to use during pregnancy? (JLA PSP Priority 11)
|JLA question ID
|Not available for this PSP
Pottinger, 2018 This systematic review concluded that the potential effect of biologics on pregnancy outcomes specifically in women with psoriasis has not been adequately studied to quantify accurately. Data on use in other indications is limited. Women of child-bearing potential should be advised routinely to use regular contraception; however, when planning conception the risks and benefits of continuing vs. stopping therapy should be discussed on a case-by-case basis. To address the clinical uncertainty, large disease-matched cohort studies are required, taking into account potential confounders such as disease activity, concomitant therapies and maternal demographics. Psoriasis-specific pharmacovigilance registries, for example the British Association of Dermatologist Biologics Intervention Register (BADBIR) in collaboration with others via the European Psoriasis Registry Network (PSONET), provide opportunity to collate such data.
|Health Research Classification System category
|Extra information provided by this PSP
|Original uncertainty examples
|What is the best treatment for pregnant women with psoriasis?
|6 uncertainties were submitted around this question
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|17 September 2018